newsfilter
← Latest News
PR Newswire·

Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors

  • Eloxx Pharmaceuticals appointed Geno Germano to its Board of Directors effective October 19, 2026.
  • Germano brings over 35 years of biopharmaceutical leadership experience, including serving as Group President of Pfizer's Global Innovative Pharmaceutical business.
  • He previously led Elucida Oncology as President & CEO, Intrexon as President, Wyeth U.S., Wyeth's Vaccines business, Johnson & Johnson, 2009-2013 Pfizer Specialty Care & Oncology units, 2009-2013 Pfizer Specialty Care & Oncology units.
  • Germano currently serves as Chairman of Entera Bio, director of Precision BioSciences, 2009-2013 Pfizer Specialty Care & Oncology units, 2009-2013 Pfizer Specialty Care & Oncology units, 2009-2013 Pfizer Specialty Care & Oncology units.
  • He previously served on boards including Sage Therapeutics, Orbital Therapeutics, Bioverativ, The Medicines Company, Zoetis, BIO, Healthcare Businesswomen's Association, 2009-2013 Pfizer Specialty Care & Oncology units, 2009-2013 Pfizer Specialty Care & Oncology units.
  • Germano holds a B.S. in Pharmacy from Albany College of Pharmacy and Health Sciences.
  • Eloxx is developing exaluren for rare kidney diseases like Alport syndrome and ADPKD to treat genetic causes via nonsense mutation readthrough.
  • Eloxx has licensed ZKN-013 to Almirall for rare dermatological diseases associated with nonsense mutations.